Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.

Inclusion Criteria for Asthma patients: Male, female, aged ≥19. Being able to provide written informed consent before the study. Patient with partially controlled asthma: Assessment of asthma control over the month preceding the use of Respicure ® by a symptomatic assessment (Tick one or two symptoms): 3. 1 Daytime symptoms more than twice a week, 3. 2 One or more nocturnal awakenings, 3. 3 Need for rescue medication more than twice a week, 3. 4 One or more activity limitations 4. Patient followed for at least a year and mastering the technique of using devices i.e. aerosols, nebulizer etc… Inclusion Criteria for COPD patients: Male, female, ≥40 years old Being able to provide written informed consent before the study. Patient with COPD stage A, B, C or D in stable condition with no exacerbations in the past 4 weeks. Patient followed for at least a year and mastering the technique of using devices i.e. aerosols, nebulizer etc… Inclusion Criteria for long covid patients: Male, female, aged ≥19. Being able to provide written informed consent before the study. Patients followed for respiratory symptoms linked to long Covid (symptoms for more than 12 weeks). Exclusion Criteria : Patient with severe asthma (for asthma groupe only) Prior use of Respicure®. Concomitant use with the following products: cytochrome P450 3A4 substrate drugs (e.g. statin, antifungals and fexofenadine), antibiotics (quinolones), immunosuppressants (cyclosporine) and glycoprotein P substrate drugs, e.g. antifungal and antiarrhythmic . Hypersensitivity to any of the ingredients. Hypersensitivity to peanuts. Concomitant intake of a product containing one or both of the active ingredients (resveratrol/quercetine). Pregnancy/ lactation. People who need to undergo surgery. Participation in another clinical study within the previous 30 days. Patient with asthma-COPD overlap syndrome or any other respiratory disease such as pneumonia, tuberculosis, pulmonary embolism, etc. Hormone-sensitive conditions such as breast cancer, uterine cancer, ovarian cancer, endometriosis or uterine fibroids. Patients requiring admission to intensive care and/or requiring respiratory assistance. Patients requiring anticoagulant treatment at curative doses.